The preference of T cell receptor β repertoire in laryngeal cancer
Medical Oncology · 04.11.2026 · 43 (12)
DOI: 10.1007/s12032-026-03473-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Oncology, online erschienen am 04.11.2026. Verfasst von Wenhui Pang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, The Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao, 266003, Shandong, China. Hauptthemen laut MEDLINE: Laryngeal Neoplasms, Lymphocytes, Tumor-Infiltrating, Receptors, Antigen, T-Cell, alpha-beta. Die Arbeit nennt 52 Literaturangaben. Gefördert von: Chronic Disease Management Research Project Grant, National Key Research and Development Programme of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Laryngeal cancer (LC), characterized by rapid local infiltration, poor prognosis, and low survival rate, is a common malignant tumor within the head and neck region. Currently, treatment outcomes for LC remain unsatisfactory, including those involving tumor-infiltrating lymphocyte (TIL) therapy, which has demonstrated effectiveness in solid tumors. The identification of specific T cell receptor (TCR) within TILs in LC may provide novel perspectives for overcoming these therapeutic challenges. In this study, we collected tumor tissues and peritumor tissues from LC patients and used immunohistochemistry to evaluate the infiltration of immune cells. The results revealed that the counts of CD3^+, CD4^+, and CD8^+ T cells were considerably enhanced in the LC compared to the peritumor group. Besides, the levels of these infiltrating immune cells exhibited a major positive correlation with serum concentrations of squamous cell carcinoma antigen (SCCA) in LC patients. Moreover, the differences in the usage of TRBV/J segments and complementarity-determining region 3 (CDR3) amino acid motifs were observed between LC and peritumor tissues by using immune repertoire sequencing (IR-Seq) to identify specific TCRs. This study delineates the specific TCR repertoires of TILs in LC patients, emphasizing their potential as candidate repertoire signatures warranting further validation for diagnosis and treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, The Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao, 266003, Shandong, China.
- State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Cancer Research Center, School of Medicine, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen University, Xiamen,…
- Department of Pathology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China.
- Department of Cardiology, Cheeloo College of Medicine, Qilu Hospital (Qingdao), Shandong University, 758 Hefei Road, Qingdao, 266035, Shandong, China. whf521168@163.com.
Förderung
- Chronic Disease Management Research Project Grant
- National Key Research and Development Programme of China
- National Natural Science Foundation of China
- Scientific Research Innovation Capability Support Project for Young Faculty
- Natural Science Foundation of Fujian Province
Zitieren
APA
Pang, W., Zhang, Z., Kang, E., Guo, Y., Liang, D., Qin, Z., Qiu, J., Wang, H., Wang, K., & Liang, Q. (2026). The preference of T cell receptor β repertoire in laryngeal cancer. Medical Oncology, 43(12). https://doi.org/10.1007/s12032-026-03473-6
Vancouver
Pang W, Zhang Z, Kang E, Guo Y, Liang D, Qin Z, et al. The preference of T cell receptor β repertoire in laryngeal cancer. Medical Oncology. 2026;43(12). doi:10.1007/s12032-026-03473-6
BibTeX
@article{Pang2026,
author = {Pang, Wenhui and Zhang, Zhenglang and Kang, Enhao and Guo, Yekun and Liang, Dapeng and Qin, Zuorong and Qiu, Jie and Wang, Hefeng and Wang, Kejia and Liang, Qing},
title = {The preference of T cell receptor β repertoire in laryngeal cancer},
journal = {Medical Oncology},
year = {2026},
volume = {43},
number = {12},
doi = {10.1007/s12032-026-03473-6}
}
EUVIMED